Anticoagulation is widely used in the inpatient setting for various indications for
both surgical and medical patients including stroke prevention in non-valvular atrial
fibrillation, prevention of venous thromboembolism in post-surgical patients, management
of acute coronary syndromes, and treatment of acute thrombosis. For patients with
acute thrombosis, anticoagulation is the key therapy to stabilize the thrombus, prevent
extension, and to prevent development of new thrombosis while risk factors are present
[
[1]
]. Despite an expanding repertoire of anticoagulation options (including low molecular
weight heparin, oral Xa inhibitors, and intravenous and oral direct thrombin inhibitors),
intravenous unfractionated heparin (IV UFH) continues to have significant use in the
inpatient setting. Due to its variable pharmacokinetics and pharmacodynamics, monitoring
and dose titration of IV UFH is required and has been primarily accomplished with
use of the activated partial thromboplastin time (aPTT), although many institutions
are increasingly using the anti-Xa [
[2]
].Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Thrombosis ResearchAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.Blood Adv. 2020; 4: 4693-4738
- Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis.Arch. Intern. Med. 2003; 163: 621-627
- College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy.Arch. Pathol. Lab. Med. Sep 1998; 122: 782-798
- Discordant partial thromboplastin time (PTT) vs anti-Xa heparin activity.Am. J. Clin. Pathol. 2019; 151: 424-432
- Monitoring of anticoagulation in thrombotic antiphospholipid syndrome.J. Thromb. Haemost. Apr 2021; 19: 892-908
- The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial.Ann. Intern. Med. 1993; 119: 874-881
- Coagulation assays.Circulation. 2005; 112: e53-e60
- Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.Am. J. Clin. Pathol. Apr 2013; 139: 450-456
- Evaluation of antifactor-Xa heparin assay and activated partial thromboplastin time values in patients on therapeutic continuous infusion unfractionated heparin therapy.. Jan-Dec 2019; 251076029619876030
- Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: a systematic review and meta-analysis.Thromb. Res. 2021; (In this issue)https://doi.org/10.1016/j.thromres.2021.10.010
Article info
Publication history
Published online: November 21, 2021
Accepted:
November 13,
2021
Received:
November 12,
2021
Identification
Copyright
© 2021 Elsevier Ltd. All rights reserved.
